Literature DB >> 34319275

Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial.

Judy Nee1, Sarah Ballou1, John M Kelley2,3, Ted J Kaptchuk2, William Hirsch1, Jesse Katon1, Vivian Cheng1, Vikram Rangan1, Anthony Lembo1, Johanna Iturrino1.   

Abstract

INTRODUCTION: Peppermint oil is often used to treat irritable bowel syndrome (IBS); however, the overall quality of previous studies is low, and findings have been heterogeneous. This study aimed to compare the effects of peppermint oil vs placebo in relieving IBS symptoms.
METHODS: In a 6-week, randomized, double-blind, placebo-controlled trial at a single academic center in the United States, individuals diagnosed with IBS (Rome IV criteria), with moderate to severe symptoms based on the IBS Severity Scoring System (IBS-SSS score ≥175), were randomized to enteric-coated peppermint oil 180 mg 3 times daily vs placebo in a 1:2 ratio. The primary outcome was mean change in IBS-SSS scores from baseline to 6-week endpoint.
RESULTS: A modified intent-to-treat analysis revealed that there were substantial mean improvements from baseline to 6-week endpoint in the main outcome measure (IBS-SSS) for both peppermint oil (90.8, SD = 75.3) and placebo (100.3, SD = 99.6). Although the peppermint oil group reported numerically lower improvement than the placebo group, the effect size was small (d = -0.11), and the difference between the groups was not statistically significant (P = 0.97). Similarly, both groups reported substantial improvements on the secondary endpoints; but again, there were no statistically significant differences between the groups on any of the secondary measures. Sensitivity analyses using multiple imputation to replace missing data produced similar results and revealed no significant differences between peppermint oil and placebo on any outcome measure. DISCUSSION: Peppermint oil and placebo both showed clinically meaningful improvement in IBS symptoms. However, there were no significant differences between the groups. Further large, rigorous trials are needed to evaluate the role of peppermint oil for the treatment of IBS.
Copyright © 2021 by The American College of Gastroenterology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34319275     DOI: 10.14309/ajg.0000000000001395

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  New mint on the block - Fresh hope for IBS treatment?

Authors:  Radislav Nakov; Henriette Heinrich
Journal:  United European Gastroenterol J       Date:  2021-11-03       Impact factor: 4.623

2.  Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline.

Authors:  Sarah Ballou; Rafla Hassan; Judy Nee; Johanna Iturrino; Vikram Rangan; Vivian Cheng; Lisa Conboy; Irving Kirsch; Anthony Lembo; Ted J Kaptchuk; John Kelley
Journal:  Clin Gastroenterol Hepatol       Date:  2022-03-23       Impact factor: 13.576

3.  Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study.

Authors:  Julia W Haas; Giulio Ongaro; Eric Jacobson; Lisa A Conboy; Judy Nee; Johanna Iturrino; Vikram Rangan; Anthony Lembo; Ted J Kaptchuk; Sarah Ballou
Journal:  BMC Psychol       Date:  2022-02-04

4.  Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial.

Authors:  Chiara Ricci; Fernando Rizzello; Maria Chiara Valerii; Enzo Spisni; Paolo Gionchetti; Silvia Turroni; Marco Candela; Federica D'Amico; Renato Spigarelli; Irene Bellocchio; Giovanni Marasco; Giovanni Barbara
Journal:  Nutrients       Date:  2022-10-10       Impact factor: 6.706

5.  Peppermint oil effects on the gut microbiome in children with functional abdominal pain.

Authors:  Santosh Thapa; Ruth Ann Luna; Bruno P Chumpitazi; Numan Oezguen; Susan M Abdel-Rahman; Uttam Garg; Salma Musaad; James Versalovic; Gregory L Kearns; Robert J Shulman
Journal:  Clin Transl Sci       Date:  2022-01-20       Impact factor: 4.438

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.